RecruitingPhase 1NCT07123415

A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

A Phase 1 Trial of APX-343A as Monotherapy or in Combination With Pembrolizumab to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy in Subjects With Advanced Solid Tumors

Sponsor

Aptabio Therapeutics, Inc.

Enrollment

110 participants

Start Date

Oct 24, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Cancer Advanced Solid Tumor (Phase 1)

Summary

This is a Phase 1, open-label, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of APX-343A monotherapy (Part A) and in combination with pembrolizumab (Part B) in subjects with advanced solid tumors.

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called APX-343A and a drug called Pembrolizumab for people with advanced solid cancer and advanced solid tumor (phase 1). The study is currently recruiting participants at 3 locations. People eligible for this study include aged 19 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAPX-343A

Oral administration twice daily

DRUGPembrolizumab

intravenous \[IV\]

Locations(3)

Seoul National University Bundang Hospital

Seongnam, South Korea

Gangnam Severance Hospital, Yonsei University Health System

Seoul, South Korea

Severance Hospital, Yonsei University Health System

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07123415

Related Trials

APG-2449 in Patients With Advanced Solid Tumors

NCT039170439 locations

A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With Ezabenlimab

NCT076076789 locations